|Tandem Diabetes Care Inc -- USA Stock|| |
USD 2.89 0.01 0.35%
CEO and President and Director
Mr. Kim D. Blickenstaff is President, Chief Executive Officer, and Director of Tandem Diabetes Care, Inc. Prior to joining our company, he served as Chairman and Chief Executive Officer of Biosite Incorporated, or Biosite, a provider of medical diagnostic products, from 1988 until its acquisition by Inverness Medical Innovations, Inc. in June 2007. Mr. Blickenstaff currently serves as Chairman of Medivation, Inc., and is a member of its audit committee. He previously served as a director of DexCom, Inc., a provider of glucose monitoring systems, from June 2001 to September 2007
Age: 63 CEO Since 2007 MBA
Blickenstaff was formerly a certified public accountant and has more than 20 years of experience overseeing the preparation of financial statements. He received a B.A. in Political Science from Loyola University, Chicago, and an M.B.A. from the Graduate School of Business, Loyola University, Chicago.
Kim Blickenstaff Latest Insider Activity
The company has return on total asset (ROA)
of (46.76) %
which means that it has lost $46.76 on every $100 spent on asset. This is way below average.
The company currently holds 75.6 M in liabilities with Debt to Equity (D/E) ratio of 8.6 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Tandem Diabetes Care Inc has Current Ratio of 1.86 which is within standard range for the sector.
Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes various solutions for people with insulindependent diabetes in the United States. Tandem Diabetes Care Inc (TNDM) is traded on NASDAQ General Markets in USA. It is located in CALIFORNIA, U.S.A and employs 482 people. Tandem Diabetes is listed under Medical Equipment category by Fama And French industry classification.